Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BLOOD PRODUCT FACT SHEET Antihemophilic Factor / von Willebrand Factor Complex Other Names Humate P® Pre-Transfusion Sample x Not Required Approval Requirements Product must be ordered by clinical hematologist or Hemophilia Clinic Nurse Practitioner with required privileges. Product Description Stable, purified, sterile, lyophilized concentrate of antihemophilic factor and von Willebrand factor prepared from human plasma. Heat treated to reduce viral transmission. Contains no preservatives. Supplied in vial sizes (Factor VIII / von Willebrand Factor): 200-300 IU / 360-840 IU 400-600 IU / 720-1680 IU 810-1200 IU / 1440-3360 IU One International Unit (IU) Factor VIII or von Willebrand Factor:Ristocetin Cofactor (vWF:RCo) is approximately equal to the level of Factor VIII or vWF:RCo found in 1 mL of fresh plasma. Reconstituted and filtered into a syringe in Transfusion Medicine. Clinical Indications o Blood Group o Group & Screen o Crossmatch Treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease (vWD), or in mild/moderate vWD where use of desmopressin is inadequate. To prevent excessive bleeding during and after surgery in patients with vWD Contraindications None known. Caution is advised in patients with known allergic reactions to constituents of the preparation. Risks Allergic and anaphylactic reactions. Intravascular hemolysis with decreasing hematocrit in patients of blood groups A, B and AB when treated with large doses of Humate P®. Thrombotic events in von Willebrand disease patients with known risk factors to thrombosis. Factor VIII inhibitor formation. As Humate P® is a plasma product there is a risk for transmission of infection. Humate P® should be given to a pregnant woman only if clearly needed. Dosage Many patients carry a Factor First card with pertinent information about their prescribed therapy. Consult with the Hematologist-on-call for dosing and prescribing guidelines The dosage must be individualized according to the needs of the patient. The product must be ordered in vWF:RCo units(Ristocetin cofactor units), not Factor VIII units. The nearest combination of whole vials must be used to deliver the prescribed dose. Administration Visually inspect for particulate matter and discolouration prior to administration. Refer to: Disclaimer Message TR.05.18 Transfusion Manual Page 1 of 2 The following information, i.e. guideline/educational material/policy or procedure, has been developed for use only within BC Children's Hospital (BC Children's) and BC Women's Hospital and Health Centre (BC Women's). Agencies other than BC Children's or BC Women's should use this information as a guideline for reference purposes only. All materials are the property of BC Children's and BC Women's and may only be reprinted in whole or in part with our expressed permission. Contact [email protected] with questions. Date/Time Generated Generated By Nov 02, 2016 10:14 Anonymous BLOOD PRODUCT FACT SHEET Antihemophilic Factor / von Willebrand Factor Complex Administering Medications Using IV Push Method Product monograph Administer: By intravenous injection only At room temperature Through a separate injection site Inject slowly to a maximum rate of 4 mL/minute. Compatible Solution The manufacturer does not recommend any compatible fluids. Flush the line before and after administration with 0.9% Normal Saline only. Do not mix with other medicinal products or intravenous admixtures. Infusion Rates Maximum infusion rate is 4 mL/minute. Monitoring Observe patient for signs and symptoms of a transfusion reaction. In the event of a suspected transfusion reaction, refer to Transfusion Reaction Procedure & Quick Reference guide and complete Transfusion Reaction Report Form. EVALUATE effectiveness of treatment. Storage Conditions Stored at room temperature, not to exceed 25 C. Home storage of Humate-P may vary from in hospital storage and does not apply in the hospital situation. For reconstituted product: Store at room temperature Administer within 3 hours of reconstitution. Return product and Transfusion Record to Transfusion Medicine within 20 minutes from time of issue if there are any delays in administration. Do not refrigerate or store on nursing unit. References Product Monograph Humate-P: CSL Behring Canada Inc, January 2013. Retrieved from: http://www.cslbehring.ca/docs/783/911/English_Humate%20P_PM.pdf Disclaimer Message TR.05.18 Transfusion Manual Page 2 of 2 The following information, i.e. guideline/educational material/policy or procedure, has been developed for use only within BC Children's Hospital (BC Children's) and BC Women's Hospital and Health Centre (BC Women's). Agencies other than BC Children's or BC Women's should use this information as a guideline for reference purposes only. All materials are the property of BC Children's and BC Women's and may only be reprinted in whole or in part with our expressed permission. Contact [email protected] with questions. Date/Time Generated Generated By Nov 02, 2016 10:14 Anonymous